Circulating angiopoietin-like protein 8 (betatrophin) association with HsCRP and metabolic syndrome

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Abu Farha, Mohamed ^a   Abubaker, Jehad ^a   Al Khairi, Irina ^a   Cherian, Preethi ^a   Noronha, Fiona ^b   Kavalakatt, Sina ^a   Khadir, Abdelkrim ^a   Behbehani, Kazem ^b   Alarouj, Monira ^b   Bennakhi, Abdullah ^b   Elkum, Naser ^c  

^a Biochemistry and Molecular Biology Unit   (Kuwait)

^b DASMAN DIABETES INSTITUTE   (Kuwait)

^c SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; BETATROPHIN; C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LIPASIN PROTEIN, HUMAN; PEPTIDE HORMONE;

ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HOMA IR; HUMAN; INFLAMMATION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; WAIST HIP RATIO; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; KUWAIT; LEAST SQUARE ANALYSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; UPREGULATION;

ADULT; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KUWAIT; LEAST-SQUARES ANALYSIS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PEPTIDE HORMONES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION;

EID: 84957062011     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0346-0     Document Type: Article

References (43)

1. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-32.
2. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2005;165(21):2479-84.
3. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-22.
4. Rezaianzadeh A, Namayandeh SM, Sadr SM. National Cholesterol Education Program Adult Treatment Panel III Versus International Diabetic Federation Definition of Metabolic Syndrome, Which One is Associated with Diabetes Mellitus and Coronary Artery Disease? Int J Prev Med. 2012;3(8):552-8.
5. Parikh R, Mohan V, Joshi S. Should waist circumference be replaced by index of central obesity (ICO) in definition of metabolic syndrome? Diabetes Metab Res Rev. 2012;28(1):3-5.
6. Zimmet P, Alberti G. The metabolic syndrome: progress towards one definition for an epidemic of our time. Nat Clin Pract Endocrinol Metab. 2008;4(5):239.
7. Miida T, Seino U, Miyazaki O, Hanyu O, Hirayama S, Saito T, Ishikawa Y, Akamatsu S, Nakano T, Nakajima K, Okazaki M, Okada M. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis. 2008;200(2):329-35.
8. Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, di Minno G, Margaglione M, Tremoli E, Kooistra T, Morange PE, Lundman P, Mohamed-Ali V, Hamsten A. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism. 2004;53(7):852-7.
9. Povel CM, Beulens JW, van der Schouw YT, Dolle ME, Spijkerman AM, Verschuren WM, Feskens EJ, Boer JM. Metabolic syndrome model definitions predicting type 2 diabetes and cardiovascular disease. Diabetes Care. 2013;36(2):362-8.
10. Rodriguez-Leal GA, Moran S, Gallardo I, Milke P, Guevara-Gonzalez L. Assessment of high sensitivity C-reactive protein (HS-CRP) as a marker of liver inflammation in patients with metabolic syndrome. Rev Gastroenterol Mex. 2006;71(1):39-45.
11. Rasouli M, Kiasari AM. Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease. Clin Biochem. 2006;39(10):971-7.
12. Devaraj S, Swarbrick MM, Singh U, Adams-Huet B, Havel PJ, Jialal I. CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers. Am J Clin Pathol. 2008;129(5):815-22.
13. Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell. 2013;153(4):747-58.
14. Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab. 2012;303(3):E334-51.
15. Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, Valenzuela DM, Murphy AJ, Cohen JC, Hobbs HH. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA. 2012;109(48):19751-6.
16. Zhang R, Abou-Samra AB. Emerging roles of Lipasin as a critical lipid regulator. Biochem Biophys Res Commun. 2013;432(3):401-5.
17. Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun. 2012;424(4):786-92.
18. Abubaker J, Tiss A, Abu-Farha M, Al-Ghimlas F, Al-Khairi I, Baturcam E, Cherian P, Elkum N, Hammad M, John J, Kavalakatt S, Khadir A, Warsame S, Dermime S, Behbehani K, Dehbi M. DNAJB3/HSP-40 cochaperone is downregulated in obese humans and is restored by physical exercise. PLoS One. 2013;8(7):e69217.
19. Gusarova V, Alexa CA, Na E, Stevis PE, Xin Y, Bonner-Weir S, Cohen JC, Hobbs HH, Murphy AJ, Yancopoulos GD, Gromada J. ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell. 2014;159(3):691-6.
20. Yi P, Park JS, Melton DA. Perspectives on the activities of ANGPTL8/betatrophin. Cell. 2014;159(3):467-8.
21. Abu-Farha M, Abubaker J, Al-Khairi I, Cherian P, Noronha F, Hu FB, Behbehani K, Elkum N. Higher plasma betatrophin/ANGPTL8 level in Type 2 Diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep. 2015;5:10949.
22. Abu-Farha M, Abubaker J, Noronha F, Al-Khairi I, Cherian P, Alarouj M, Bennakhi A, Elkum N. Lack of associations between betatrophin/ANGPTL8 level and C-peptide in type 2 diabetic subjects. Cardiovasc Diabetol. 2015;14:112.
23. Abu-Farha M, Behbehani K, Elkum N. Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs. Cardiovasc Diabetol. 2014;13:76.
24. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2008;31(Suppl 1):S55-60.
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-72.
26. Li Y, Teng C. Angiopoietin-like proteins 3, 4 and 8: regulating lipid metabolism and providing new hope for metabolic syndrome. J Drug Target. 2014;22(8):679-87.
27. Santulli G. Angiopoietin-like proteins: a comprehensive look. Front Endocrinol (Lausanne). 2014;5:4.
28. Kadomatsu T, Tabata M, Oike Y. Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. FEBS J. 2011;278(4):559-64.
29. Oike Y, Akao M, Kubota Y, Suda T. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med. 2005;11(10):473-9.
30. Zhang R, Abou-Samra AB. A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy. Cardiovasc Diabetol. 2014;13:133.
31. Espes D, Martinell M, Carlsson PO. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int J Endocrinol. 2014;2014:323407.
32. Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep. 2014;4:5013.
33. Hu H, Sun W, Yu S, Hong X, Qian W, Tang B, Wang D, Yang L, Wang J, Mao C, Zhou L. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care. 2014;37(10):2718-22.
34. Gao T, Jin K, Chen P, Jin H, Yang L, Xie X, Yang M, Hu C, Yu X. Circulating Betatrophin Correlates with Triglycerides and Postprandial Glucose among Different Glucose Tolerance Statuses-a Case-Control Study. PLoS One. 2015;10(8):e0133640.
35. Gokulakrishnan K, Manokaran K, Pandey GK, Amutha A, Ranjani H, Anjana RM, Mohan V. Relationship of betatrophin with youth onset type 2 diabetes among Asian Indians. Diabetes Res Clin Pract. 2015;109(1):71-6.
36. Gómez-Ambrosi J, Pascual E, Catalán V, Rodríguez A, Ramírez B, Silva C, Gil MJ, Salvador J, Frühbeck G. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab. 2014;99(10):E2004-9.
37. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet. 2005;366(9491):1059-62.
38. Devaraj S, Valleggi S, Siegel D, Jialal I. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep. 2010;12(2):110-8.
39. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-28.
40. Abu-Farha M, Sriraman D, Cherian P, AlKhairi I, Elkum N, Behbehani K, Abubaker J. Circulating ANGPTL8/Betatrophin Is Increased in Obesity and Reduced after Exercise Training. PLoS One. 2016;11(1):e0147367.
41. Fu Z, Abou-Samra AB, Zhang R. An explanation for recent discrepancies in levels of human circulating betatrophin. Diabetologia. 2014;57(10):2232-4.
42. Tjeerdema N, Georgiadi A, Jonker JT, van Glabbeek M. Alizadeh Dehnavi R, Tamsma JT, Smit JW, Kersten S, Rensen PC: Inflammation increases plasma angiopoietin-like protein 4 in patients with the metabolic syndrome and type 2 diabetes. BMJ Open Diabetes Res Care. 2014;2(1):e000034.
43. Mehta N, Qamar A, Qu L, Qasim AN, Mehta NN, Reilly MP, Rader DJ. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits. Arterioscler Thromb Vasc Biol. 2014;34(5):1057-63.